In summary, these data demonstrate that combination of RASG12C(ON) and SHP2 inhibition can activate adaptive immune responses, suppress tumour relapse, and synergise with anti-PD-1 immunotherapy to generate complete cures at high frequency in immunogenic mouse models of NSCLC. This evidence concerns the gene PDCD1 and neoplasm.